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Ipratropium, a short-acting anticholinergic bronchodila-
tor, is frequently prescribed for the maintenance treat-
ment of COPD. Tiotropium is a new, once-daily bron-
chodilator.
OBJECTIVE: To compare the costs and consequences of
tiotropium versus ipratropium in COPD patients with a
FEV 1 65% of predicted normal.
METHODS: The cost-consequence analysis was part of a
one-year, randomized, controlled, double-blind clinical
trial in the Netherlands and Belgium. Consequences were
expressed as the number of COPD exacerbations, the
number of patients with a minimal clinically relevant im-
provement in the St. George’s Respiratory Questionnaire
(SGRQ), and the number of effectively treated patients.
A societal perspective was adopted when calculating
COPD-related direct health-care costs. Multiple imputa-
tion (SOLAS) was used to impute all missing data.
RESULTS: Tiotropium was associated with a 27% re-
duction in exacerbations (p  0.03). The number of pa-
tients with a clinically relevant improvement in SGRQ af-
ter one year of treatment was 16% higher in tiotropium
(p  .001). The proportion of effectively treated patients
was 21% higher (p  .001). Across all categories, health-
care resource use was consistently lower for tiotropium
than for ipratropium. There was a 47% reduction (p 
0.07) in the number of hospital admissions and a 36%
reduction (p  0.03) in the number of unscheduled visits
to physicians and other caregivers. The use of concomi-
tant medication was comparable in both groups. COPD-
related health-care costs were estimated to be Euro 1310
in ipratropium and Euro 1065 in tiotropium. Hence, an-
nual savings were estimated to be Euro 245 with a 95%
CI ranging from 656 to 167. This estimate excludes
the costs of the study medications, since the price of
tiotropium still has to be set.
CONCLUSION: This cost-consequence analysis favors
the new once daily bronchodilator tiotropium over iprat-
ropium on all relevant outcome measures.
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OBJECTIVE: To determine if lost productive work time
differed between individuals with and without AR symp-
toms and by severity of AR symptoms. Work loss was
evaluated as: a) missed workdays; b) missed hours, and c)
reduced productivity on days at work while not feeling
well.
METHODS: Three different phone interviews were de-
veloped to quantify illness-related work loss. Version 1
(V1) included a lengthy direct assessment of work loss.
Version 2 (V2) was an abridged version of V1. Version 3
(V3) included a brief indirect assessment of work loss.
Two different recall periods, at one week and at four
weeks, were used for each version of the interview. A
convenience sample (n  20,088) of adult residents from
the Baltimore, MD and Chicago, IL areas was contacted
by phone, of whom 7,691 met occupation eligibility cri-
teria. The interview included health questions to screen
for AR symptoms and to determine AR severity.
RESULTS: The dominant source of health-related work
loss among all respondents was in total hours of reduced
productive work time on days at work when not feeling
well, rather than missed full days of work. We compared
individuals with AR symptoms (n  1,596) to controls
without AR symptoms on the basis of estimates of total
hours of lost productive work time per week by interview
version. AR cases reported significantly more lost pro-
ductive work hours per week than controls. The observed
differences between cases and controls per week were 1.8
hours (V1), 2.1 hours (V2), and 3.1 hours (V3) (p  .05).
Among moderate-to-severe AR cases, the observed differ-
ences per week increased to 4.4 hours (V1), 5.7 hours
(V2), and 6.5 hours (V3).
CONCLUSION: Individuals with AR symptoms re-
ported significantly more lost productive time at work on
days at work when not feeling well than controls. Hours
of lost productive work time per week increased with in-
creased severity of AR symptoms.
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OBJECTIVES: To assess the impact of an intervention
helping physicians in the management of asthma patients
(APs).
METHODS: A program was designed to help physicians
in the management of APs that includes an education
program (EP) and a computer application (CA) advising
on therapeutic decisions. The EP was devoted to teach
patients to distinguish worsening symptoms requiring a
hospital emergency visit from those that could be self-
managed, and to ensure correct self-administration/self-
control of therapy. The CA implements the Spanish rec-
ommendations for the management of APs that physi-
cians may follow at their discretion. A naturalistic, con-
trolled, cluster-randomized study was designed to assess
the long-term (one-year) impact of the intervention on
health-related quality of life as measured by the St.
George’s Respiratory Questionnaire (SGRQ), on direct
and indirect costs, and on satisfaction and clinical out-
comes. We also assessed physicians’ adherence to the rec-
ommendations. Twenty-two physicians (11 GPs, 11 pneu-
